SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
J&J’s Single-Dose COVID-19 Vaccine Generates Strong Immune Response, Early Data Shows
The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
September 28, 2020
 · 
2 min read
 · 
Alex Keown
Pharm Country
Clinical Catch-Up: September 21-25
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
September 24, 2020
 · 
13 min read
 · 
Mark Terry
Drug Development
Another One Down: AC Immune and Genentech’s Tau Drug Fails Alzheimer’s Trial
The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints.
September 23, 2020
 · 
4 min read
 · 
Mark Terry
Drug Development
Arcturus CEO: Investigational COVID-19 Vaccine Could Play Notable Role in Managing the Pandemic
Arcturus CEO Joseph Payne told BioSpace in an interview that his company’s vaccine candidate is a low-dose, single-shot treatment that generated not only neutralizing antibody titers, but also CD8+ T-cell induction in preclinical studies.
September 22, 2020
 · 
3 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: October 2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 2, 2020.
September 22, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 30
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
September 22, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: September 28
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
September 22, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 25
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
September 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: September 23
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
September 22, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma.
September 22, 2020
 · 
3 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
April 21, 2024
 · 
3 min read
Drug Development
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
April 19, 2024
 · 
4 min read
Drug Development
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV CureStudy will enroll participants who initiated treatment shortly after acquiring HIV
April 19, 2024
 · 
4 min read
Drug Development
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024
 · 
5 min read
Drug Development
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024
 · 
8 min read
Drug Development
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
April 18, 2024
 · 
5 min read
Drug Development
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024
 · 
8 min read
Drug Development
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
April 18, 2024
 · 
5 min read
Drug Development
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
April 17, 2024
 · 
7 min read
Drug Development
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
 · 
10 min read
Drug Development
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
April 17, 2024
 · 
5 min read
Drug Development
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
April 17, 2024
 · 
6 min read
Drug Development
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024
 · 
6 min read
Drug Development
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
April 17, 2024
 · 
4 min read
Drug Development
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
April 17, 2024
 · 
7 min read
Drug Development
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
April 17, 2024
 · 
6 min read
Drug Development
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
April 17, 2024
 · 
8 min read
Drug Development
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
April 16, 2024
 · 
7 min read
Drug Development
Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease
April 16, 2024
 · 
3 min read
Drug Development
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
April 16, 2024
 · 
2 min read
Load More